J. Goldman & CO LP Tarsus Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 140,288 shares of TARS stock, worth $5.9 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
140,288
Previous 130,195
7.75%
Holding current value
$5.9 Million
Previous $7.21 Million
0.03%
% of portfolio
0.19%
Previous 0.2%
Shares
14 transactions
Others Institutions Holding TARS
# of Institutions
201Shares Held
44.5MCall Options Held
19.9KPut Options Held
7.6K-
Rtw Investments, LP New York, NY3.32MShares$139 Million2.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$137 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.61MShares$110 Million6.87% of portfolio
-
Jennison Associates LLC2.49MShares$105 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$103 Million8.19% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.12B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...